DSM has added Kremer Method™, an innovative proprietary technology to improve downstream processing of monoclonal antibodies for faster and more cost effective production of biopharmaceuticals. The Kremer Method reduces processing and preparation times, labor and materials requirements and cost of goods for a more sustainable manufacturing platform, according to DSM. Karen King, president of DSM Biologics, commented, “DSM is continually innovating to advance the world of biopharmaceutical...